Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma.
Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma. – Nanotechnology News Today – EIN Presswire
Trusted News Since 1995
A service for nanotechnology industry professionals
·
Tuesday, January 24, 2023
·
613,065,610
Articles
·
3+ Million Readers
